Immunotherapy/Targeted Therapy Combinations Show Promise in BRAF-Mutated Melanoma – Targeted Oncology
Targeted Oncology |
Immunotherapy/Targeted Therapy Combinations Show Promise in BRAF-Mutated Melanoma
Targeted Oncology Triplet therapy with the combination of anti–PD-1/PD-L1 therapy, BRAF, and MEK inhibitors have already shown promise for patients with BRAF-positive advanced melanoma, and the potential for these combinations are increasing, according to Antoni Ribas, … |
